<DOC>
	<DOCNO>NCT02735421</DOCNO>
	<brief_summary>This multi-centre , randomize , investigator blind , vehicle control trial use intra-individual comparison ( right half-face versus leave half-face ) . Subjects half-face randomized one two follow treatment : - Adapalene 0.3 % - BPO 2.5 % gel ( TactuPump® Forte ) . - Vehicle gel The main objective trial evaluate effect Adapalene 0.3 % - benzoyl peroxide ( BPO ) 2.5 % gel versus vehicle gel risk formation atrophic acne scar moderate severe acne subject .</brief_summary>
	<brief_title>Adapalene 0.3 % - Benzoyl Peroxide 2.5 % Gel Risk Formation Atrophic Acne Scars</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Main Subject clinical diagnosis moderate severe acne vulgaris face define : 1 . Investigator 's Global Assessment score 3 4 , score side ; 2 . A minimum 25 inflammatory lesion ( papule pustule ) total , least 10 side ( exclude nose ) ; 3 . No two acne nodule ( ≥ 1 cm ) ; 4 . A minimum 10 atrophic acne scar total ( upper 2 mm ) ( exclude nose ) . Subject symmetric number inflammatory noninflammatory lesion whole face , atrophic acne scar whole face Subject skin phototype I IV Fitzpatrick 's scale Main Subject acne conglobata , acne fulminans , secondary acne ( chloracne , druginduced acne , etc . ) , nodulo cystic acne , acne require systemic treatment . Prior failure treatment TactuPump® Forte ( Adapalene 0.3 % BPO 2.5 % ) . Subject 3 excoriate acne lesion . Subject skin abrade treated area affect eczema , seborrhoeic dermatitis , cut sunburn . Female subject pregnant , nurse plan pregnancy trial within one month last trial treatment application Male subject beard facial hair , would interfere clinical trial evaluation clinical trial procedure Subject receive least one follow topical treatment treat area : Corticosteroids , antibiotic , benzoyl peroxide , azelaic acid , hydroxyacids , Zinc contain treatment , antibacterial , antiseptic , antiinflammatory drug acne treatment ( 2 week ) ; Retinoids ( 4 week ) ; Cosmetic/aesthetic procedure face ( 1 week ) ; Photodynamic therapy , laser therapy , microdermabrasion acne ( 3 month ) Subject receive least one follow systemic treatment : Corticosteroids ( except locally act corticosteroid inhale intrathecal dermal application distance face ) , antibiotic ( except penicillin ) ( 1 month ) ; Spironolactone ( 3 month ) / Drospirenone ( 3 month , unless dose stable since least 3 month ) ; Oral retinoids ( 6 month ) ; Cyproterone acetate / Chlormadinone acetate ( 6 month ) ; Immunomodulators ( 3 month )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>acne</keyword>
	<keyword>scar</keyword>
</DOC>